Adiponectin (mouse) ELISA Kit

AdipoGen Life Sciences

Adiponectin (mouse) ELISA Kit

10

ELISA

0.125 to 8ng/ml

50pg/ml

Detects mouse adiponectin. Does not cross-react with human adiponectin, rat adiponectin, mouse resistin, mouse RELM-beta or mouse leptin.

Research Use Only

Adiponectin [ACRP30; AdipoQ] is a promising biomarker of insulin resistance and type 2 diabetes mellitus (T2DM) but also as a potential target for management of the metabolic syndrome. It is a very robust marker that is not prone to degradation or acute inflammatory challenges, is present in relatively high concentrations in the peripheral circulation, and can be collected by a variety of methods. The benefits of using adiponectin assays in clinical settings include, (a) prediction of risk of diabetes and metabolic status and (b) providing a tool to monitor metabolic improvements. Adiponectin exerts anti-atherogenic and anti-inflammatory properties and may be important as a biomarker for obesity-related cardiovascular disease (CVD). New findings showed urinary adiponectin excretion as an independent new biomarker of microvascular and macrovascular damage in T2DM and suggested it as a very promising tool for early cardiovascular disease risk assessment. Adiponectin serum level was also described as a good biomarker of colorectal adenoma, this being related to the positive correlation between obesity and increased risk of cancer at various sites (colorectal, breast, prostate and endometrium). - ELISA Assay. Detects mouse adiponectin. Does not cross-react with human adiponectin, rat adiponectin, mouse resistin, mouse RELM-beta or mouse leptin. Colorimetric assay. Sample Types: Cell Culture Supernatant, Plasma, Serum. Range: 0.125 to 8ng/ml. Sensitivity: 50pg/ml. Adiponectin is a promising biomarker of insulin resistance and type 2 diabetes mellitus (T2DM) but also as a potential target for management of the metabolic syndrome. It is a very robust marker that is not prone to degradation or acute inflammatory challenges, is present in relatively high concentrations in the peripheral circulation, and can be collected by a variety of methods. The benefits of using adiponectin assays in clinical settings include, (a) prediction of risk of diabetes and metabolic status and (b) providing a tool to monitor metabolic improvements. Adiponectin exerts anti-atherogenic and anti-inflammatory properties and may be important as a biomarker for obesity-related cardiovascular disease (CVD). New findings showed urinary adiponectin excretion as an independent new biomarker of microvascular and macrovascular damage in T2DM and suggested it as a very promising tool for early cardiovascular disease risk assessment. Adiponectin serum level was also described as a good biomarker of colorectal adenoma, this being related to the positive correlation between obesity and increased risk of cancer at various sites (colorectal, breast, prostate and endometrium).

2°C to 8°C

41116158